Regulonix Holding
Dr. Zamponi is an active University researcher, lecturer and student advisor as well as a noted speaker at major neuroscience, pharmacology and cell biology scientific symposia and educational events worldwide. With nearly three decades of experience specializing in voltage gated calcium channels, how they are compromised in various neurological disorders and how they can be targeted to develop new pain therapeutics, Dr. Zamponi is a recognized expert in the pain field. He has earned nearly three dozen global awards, is a member on numerous provincial, national and international committees, and has been issued 11 US and 46 International Patents. Additionally, Dr. Zamponi has served on numerous pharmaceutical and biotech company scientific advisory boards, founded a pharmaceutical startup, and his over 600 peer-reviewed publications, abstracts and presentations have been cited over 11,000 times.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Regulonix Holding
Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine.